Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Not applicable Interventional Results available

A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols

ClinicalTrials.gov ID: NCT01369433

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01369433. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 8:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Open-label, multi-center, multi-national rollover study to allow continued access to tivozanib for subjects who have participated in other tivozanib (monotherapy or combination) protocols. Eligible subjects will continue to receive tivozanib at the same dose and schedule as per the original (parent) protocol. The length of time that a subject must be on the parent protocol before rolling over to this protocol will be dictated by the (original) parent protocol. Subjects will be seen by the investigator every 4 weeks (± 5 days). Adverse events and blood pressure will be recorded. At the beginning of Cycle 1 and at the beginning of every odd-numbered cycle (Cycle 3, Cycle 5, etc), clinical laboratory values will be recorded. CT scans to assess disease will be performed at the end of even-numbered cycles (Cycle 2, Cycle 4, etc).

Study identification

NCT ID
NCT01369433
Recruitment status
Terminated
Study type
Interventional
Phase
Not applicable
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Enrollment
225 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 2010 (Type not available)
Primary completion
Jun 2015 (Actual)
Completion
Oct 2015 (Actual)
Last update posted
Sep 1, 2020

2010 – 2015

United States locations

U.S. sites
27
U.S. states
21
U.S. cities
27
Facility City State ZIP Site status
Translational Genomics Research Institute (TGEN) Scottsdale Arizona 85258 —
Institute of Urologic Oncology Los Angeles California 90024 —
Stanford University Stanford California 94305 —
Not listed Aurora Colorado 80010 —
Florida Cancer Specialists Fort Myers Florida 33905 —
H. Lee Moffitt Cancer Center & Research Institute Hospital, Inc Tampa Florida 33612 —
Not listed Beech Grove Indiana 46107 —
Horizon Oncology Research, Inc. Lafayette Indiana 47905 —
Not listed Wichita Kansas 57217 —
Medical Oncology LLC Baton Rouge Louisiana 70801 —
Jayne Gurtler MD, Laura Brinz MD, Angelo Russo MD and Janet Burroff MD APMC Metairie Louisiana 70006 —
Associates in Oncology/Hematology Rockville Maryland 20850 —
Dana Farber Cancer Institute Boston Massachusetts 02115 —
Not listed Grand Rapids Michigan 49501 —
Not listed Tupelo Mississippi 38801 —
Nebraska Methodist Hospital Omaha Nebraska 68114 —
Not listed Las Vegas Nevada 88901 —
Not listed Lebanon New Hampshire 03748 —
Not listed Chapel Hill North Carolina 27514 —
Not listed Columbus Ohio 43004 —
The OU Cancer Institute Oklahoma City Oklahoma 73117 —
Not listed Philadelphia Pennsylvania 19019 —
Sarah Cannon Research Institute (SCRI) Nashville Tennessee 37203 —
Not listed Austin Texas 73301 —
Coastal Bend Cancer Center Corpus Christi Texas 78336 —
Not listed Dallas Texas 75001 —
Not listed Tacoma Washington 98402 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01369433, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 1, 2020 · Synced Nov 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.